The rise and fall of natriuretic peptides in acute kidney injury: A misunderstood relationship?

Reviews in Cardiovascular Medicine

Volumn 8, Issue SUPPL. 5, 2007, Pages

  Ejaz, A Ahsan ^a   Heinig, Marcelo E ^a   Kazory, Amir ^a   Bihorac, Azra ^a,b   Hobson, Charles E ^a   Beaver, Thomas M ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Acute kidney injury; Natriuretic peptides

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; NESIRITIDE;

ACUTE DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; HUMAN; HYPOTENSION; KIDNEY BLOOD FLOW; KIDNEY DYSFUNCTION; KIDNEY INJURY; NATRIURESIS; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT OUTCOME; VASODILATATION;

ATRIAL NATRIURETIC FACTOR; BLOOD CIRCULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY FAILURE, ACUTE; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; VASODILATION;

EID: 38349077481     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Allgren RL, Marbury TC, Rahman SN, et al. Anaritide in acute tubular necrosis. Auriculin Anaritide Acute Renal Failure Study Group. N Engl J Med. 1977;336:828-834.
2. Lewis J, Salem MM, Chertow GM, et al. Atrial natriuretic factor in oliguric acute renal failure. Anaritide Acute Renal Failure Study Group. Am J Kidney Dis. 2000;36:767-774.
3. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000;343:246-253.
4. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487-1491.
5. Sward K, Valsson F, Odencrants P, et al. Recombinant human atrial natriuretic peptide in ischemic acute renal failure: a randomized placebo-controlled trial. Crit Care Med. 2004;32:1310-1315.
6. Beaver TM, Winterstein AG, Shuster JJ, et al. Effectiveness of nesiritide on dialysis or all-cause mortality in patients undergoing cardiothoracic surgery. Clin Cardiol. 2006;29:18-24.
7. Pidgeon GB, Richards AM, Nicholls MG, et al. Differing metabolism and bioactivity of atrial and brain natriuretic peptides in essential hypertension. Hypertension. 1996;27:906-913.
8. Huang CL, Lewicki J, Johnson LK, Cogan MG. Renal mechanism of action of rat atrial natriuretic factor. J Clin Invest. 1985;75:769-773.
9. Lanese DM, Yuan BH, Falk SA, Conger JD. Effects of atriopeptin III on isolated rat afferent and efferent arterioles. Am J Physiol. 1991;261: F1102-F1109.
10. Huxley VH, Tucker VL, Verburg KM, Freeman RH. Increased capillary hydraulic conductivity induced by atrial natriuretic peptide. Circ Res. 1987;60:304-307.
11. McKay MK, Huxley VH. ANP increases capillary permeability to protein independent of perfusate protein composition. Am J Physiol. 1995;268:H1139-1148.
12. Houben AJ, van der Zander K, de Leeuw PW. Vascular and renal actions of brain natriuretic peptide in man: physiology and pharmacology. Fundam Clin Pharmacol. 2005;19:411-419.
13. Potter AA, Wallace AM, Ferraris VA, Weishaar RE. Relaxant effect of human natriuretic peptide on human artery and vein tissue. Am J Hypertens. 1996;9:432-436.
14. Rahman SN, Kim GE, Mathew AS, et al. Effects of atrial natriuretic peptide in clinical acute renal failure. Kidney Int. 1994;45:1731-1738.
15. Valsson F, Ricksten SE, Hedner T, Lundin S. Effects of atrial natriuretic peptide on acute renal impairment in patients with heart failure after cardiac surgery. Intensive Care Med. 1996;22:230-236.
16. Sward K, Valson F, Ricksten SE. Long-term infusion of atrial natriuretic peptide (ANP) improves renal blood flow and glomerular filtration rate in clinical acute renal failure. Acta Anaesthesiol Scand. 2001;45:536-542.
17. Mentzer RM Jr, Oz MC, Sladen RN, et al; on behalf of the NAPA Investigators. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA Trial. J Am Coll Cardiol. 2007;49:716-726.
18. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293:1900-1905.
19. Aaronson KD, Sackner-Bernstein J. Risk of death associated with nesiritide in patients with acutely decompensated heart failure. JAMA. 2006;296:1465-1466.
20. Hauptman PJ, Schnitzler MA, Swindle J, Burroughs TE. Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure. JAMA. 2006;296:1877-1884.
21. Burger AJ, Horton DP, LeJemtel T, et al; Prospective Randomized Evaluation of Cardiac Ectopy with Dobutamine or Natrecor Therapy. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J. 2002;144:1102-1108.
22. Peacock WF, Emerman CL, Silver MA. Nesiritide added to standard care favorably reduces systolic blood pressure compared with standard care alone in patients with acute decompensated heart failure. Am J Emerg Med. 2005;23:327-331.
23. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531-1540.
24. Yancy CW, Saltzberg MT, Berkowitz RL, et al. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial). Am J Cardiol. 2004;94:595-601.
25. Jensen KT, Carstens J, Pedersen EB. Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans. Am J Physiol. 1998;274:F63-F72.
26. Lazzeri C, La Villa G, Bisi G, et al. Cardiovascular function during brain natriuretic peptide infusion in man. Cardiology. 1995;86:396-401.
27. La Villa G, Stefani L, Lazzeri C, et al. Acute effects of physiological increments of brain natriuretic peptide in humans. Hypertension. 1995; 26:628-633.
28. La Villa G, Fronzaroli C, Lazzeri C, et al. Cardiovascular and renal effects of low dose brain natriuretic peptide infusion in man. J Clin Endocrinol Metab. 1994;78:1166-1171.
29. Holmes SJ, Espiner EA, Richards AM, et al. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab. 1993;76:91-96.
30. Yoshimura M, Yasue H, Morita E, et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation. 1991;84:1581-1588.
31. McGregor A, Richards M, Espiner E, et al. Brain natriuretic peptide administered to man: actions and metabolism. J Clin Endocrinol Metab. 1990;70:1103-1107.
32. Cheung BM, Dickerson JE, Ashby MJ, et al. Effects of physiological increments in human alpha-atrial natriuretic peptide and human brain natriuretic peptide in normal male subjects. Clin Sci (Lond). 1994;86:723-730.
33. van der Zander K, Houben AJ, Hofstra L, et al. Hemodynamic and renal effects of low-dose brain natriuretic peptide infusion in humans: a randomized, placebo-controlled crossover study. Am J Physiol Heart Circ Physiol. 2003;285: H1206-H1212.
34. Yasue H, Yoshimura M. Natriuretic peptides in the treatment of heart failure. J Card Fail. 1996;2:S277-S285.
35. Lazzeri C, Franchi F, Porciani C, et al. Systemic hemodynamics and renal function during brain natriuretic peptide infusion in patients with essential hypertension. Am J Hypertens. 1995;8:799-807.
36. Richards AM, Crozier IG, Holmes SJ, et al. Brain natriuretic peptide: natriuretic and endocrine effects in essential hypertension. J Hypertens. 1993;11:163-170.
37. Lainchbury JG, Richards AM, Nicholls MG, et al. The effects of pathophysiological increments in brain natriuretic peptide in left ventricular systolic dysfunction. Hypertension. 1997;30: 398-404.
38. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation. 1996;94:3184-3189.
39. Kelleher SP, Robinette JB, Conger JD. Sympathetic nervous system in the loss of autoregulation in acute renal failure. Am J Physiol. 1984;246:F379-F386.
40. Molitoris BA. Transitioning to therapy in ischemic acute renal failure. J Am Soc Nephrol. 2003;14:265-267.
41. Chertow GM, Lazarus JM, Christiansen CL, et al. Preoperative renal risk stratification. Circulation. 1997;95:878-884.